REMINDER: Akers Biosciences Schedules Conference Call to Discuss Merger with MyMD Pharmaceuticals Baltimore, Maryland

Akers Biosciences Schedules Conference Call to Discuss Merger with MyMD Pharmaceuticals

Maryland, November 18, 2020 (BUSINESSWIRE) - MyMD Pharmaceuticals, Inc. ("MyMD") and Akers Biosciences,

Inc. ("Akers") (NASDAQ: AKER) jointly announced a definitive merger agreement last week. The companies plan to hold

a video conference for investors on Wednesday, November 18, 2020 at 4:15 p.m. ET to provide additional context on the integrated

company, the clinical pipeline and drug development plan, and the commercial potential of the targeted indications.

participate in the briefing session, please click on the link below to register.

Akers Biosciences Inc.

Biosciences is pursuing rapid development and manufacturing of a COVID-19 vaccine candidate in collaboration with Premas Biotech

MyMD Pharmaceuticals, Inc:

is a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms.

MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immunometabolic system to control TNF-

and other pro-inflammatory cytokines. MYMD-1 is being developed to treat autoimmune diseases, including those currently treated

with TNF- blocking drugs, and aging and longevity. SUPERA-1R is a drug platform based on a novel (patent pending) synthetic

derivative of cannabidiol (CBD) that targets numerous key receptors including CB2 and opioid receptors and inhibits monoamine

oxidase. SUPERA-1R is being developed to address the rapidly growing CBD market, that includes FDA approved drugs and CBD products

not currently regulated as a drug. For more information, visit www.mymd.com.

Offer or Solicitation

communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to

buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would

be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No public offer of securities

shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Additional Information Will be Filed with the SEC

connection with the proposed transaction between Akers and MyMD, Akers intends to file relevant materials with the SEC, including

a registration statement that will contain a proxy statement and prospectus. AKERS URGES INVESTORS AND STOCKHOLDERS TO READ THESE

MATERIALS CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT AKERS,

THE PROPOSED TRANSACTION AND RELATED MATTERS. Investors and shareholders will be able to obtain free copies of the proxy statement,

prospectus and other documents filed by Akers with the SEC (when they become available) through the website maintained by the

SEC at www.sec.gov. In addition, investors and shareholders will be able to obtain free copies of the proxy statement, prospectus

and other documents filed by Akers with the SEC by contacting Investor Relations by mail at Akers Biosciences, Inc., Attn: Investor

Relations, 201 Grove Road, West Deptford, NJ 08086. Investors and stockholders are urged to read the proxy statement, prospectus

and the other relevant materials when they become available before making any voting or investment decision with respect to the

proposed transaction.

and MyMD, and each of their respective directors and executive officers and certain of their other members of management and employees,

may be deemed to be participants in the solicitation of proxies in connection with the proposed transaction. Information about

Akers' directors and executive officers is included in Akers' Annual Report on Form 10-K for the year ended December

31, 2019, filed with the SEC on March 25, 2020, as amended on October 21, 2020, and the proxy statement for Akers' 2020

annual meeting of stockholders, filed with the SEC on July 29, 2020. Additional information regarding these persons and their

interests in the transaction will be included in the proxy statement relating to the transaction when it is filed with the SEC.

These documents can be obtained free of charge from the sources indicated above.

Statement Regarding Forward-Looking Statements

statements contained in this communication regarding matters that are not historical facts are forward-looking statements within

the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securities Litigation Reform

Act of 1995, known as the PSLRA. These include statements regarding management's intentions, plans, beliefs, expectations

or forecasts for the future, and, therefore, you are cautioned not to place undue reliance on them. No forward-looking statement

can be guaranteed, and actual results may differ materially from those projected. Akers and MyMD undertake no obligation to publicly

update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent

required by law. We use words such as "anticipates," "believes," "plans," "expects,"

"projects," "future," "intends," "may," "will," "should,"

"could," "estimates," "predicts," "potential," "continue," "guidance,"

and similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions

of the PSLRA. Such forward-looking statements are based on our expectations and involve risks and uncertainties; consequently,

actual results may differ materially from those expressed or implied in the statements due to a number of factors, including,

but not limited to, risks relating to the completion of the merger, including the need for stockholder approval and the satisfaction

of closing conditions; the cash balances of the combined company following the closing of the merger; the ability of Akers to

remain listed on the Nasdaq Capital Market in connection with the merger; and expected merger-related cash outlays, including

the timing and amount of those outlays. Risks and uncertainties related to MyMD that may cause actual results to differ materially

from those expressed or implied in any forward-looking statement include, but are not limited to: the timing of, and MyMD's

ability to, obtain and maintain regulatory approvals for clinical trials of MyMD's pharmaceutical candidates, the timing

and results of MyMD's planned clinical trials for its pharmaceutical candidates, the amount of funds MyMD requires for its

pharmaceutical candidates; increased levels of competition; changes in political, economic or regulatory conditions generally

and in the markets in which MyMD operates; MyMD's ability to retain and attract senior management and other key employees;

MyMD's ability to quickly and effectively respond to new technological developments; MyMD's ability to protect its

trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others

from infringing on MyMD's proprietary rights; and the impact of the ongoing COVID-19 pandemic on MyMD's results of

operations, business plan and the global economy.

factors emerge from time to time and it is not possible for us to predict all such factors, nor can we assess the impact of each

such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially

from those contained in any forward-looking statements. These risks, as well as other risks associated with the combination, will

be more fully discussed in the proxy statement/prospectus that will be included in the registration statement that will be filed

with the SEC in connection with the proposed transaction. Additional risks and uncertainties are identified and discussed in the

"Risk Factors" section of Akers' Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other documents

filed from time to time with the SEC. Forward-looking statements included in this release are based on information available to

Akers and MyMD as of the date of this release. Neither Akers nor MyMD undertakes any obligation to update such forward- looking

statements to reflect events or circumstances after the date of this release.

Brett Mass, Managing Partner

Phone: (646) 536-7331

Email: brett@haydenir.com